Azenta, Inc. (AZTA): Canvas du modèle d'entreprise [Jan-2025 Mis à jour]

Dans le paysage dynamique de l'innovation scientifique, Azenta, Inc. (AZTA) apparaît comme une puissance de précision technologique, pontant stratégiquement les mondes complexes des sciences de la vie et des technologies de semi-conductrices. Avec un modèle commercial complexe qui se tient ensemble de recherche de pointe, de fabrication avancée et de solutions spécialisées, Azenta transforme les défis scientifiques en opportunités de percée dans les domaines pharmaceutique, biotechnologie et de recherche. Leur approche unique combine des systèmes de stockage cryogénique sophistiqués, des équipements de haute précision et un engagement profond envers les progrès technologiques qui les distinguent sur un marché mondial en évolution rapide.

Azenta, Inc. (AZTA) - Modèle commercial: partenariats clés

Collaborations stratégiques avec des institutions de recherche en sciences de la vie

Azenta, Inc. maintient des partenariats stratégiques avec les institutions de recherche suivantes:

Institution de recherche	Focus de partenariat	Année établie
École de médecine de Harvard	Technologies de bioprocesse avancées	2022
Institut du MIT Whitehead	Solutions génomiques de gestion des échantillons	2021

Partenariats avec des sociétés pharmaceutiques et biotechnologiques

Les principaux partenariats pharmaceutiques et biotechnologiques comprennent:

• Pfizer Inc. - Gestion et logistique des échantillons collaboratifs
• Moderna Therapeutics - Advanced Biorepository Solutions
• Bristol Myers Squibb - Provision Technologies de la chaîne du froid

Relations des fournisseurs avec les fabricants avancés de matériaux et d'équipements

Les relations critiques des fournisseurs englobent:

Fournisseur	Catégorie d'approvisionnement	Valeur du contrat annuel
Thermo Fisher Scientific	Équipement de laboratoire	12,5 millions de dollars
Corning Incorporated	Matériaux avancés	8,3 millions de dollars

Alliances avec des centres de recherche universitaire et des universités

Partenariats de recherche universitaire importants:

• Université de Stanford - Collaboration de recherche en bio-ingénierie
• Université Johns Hopkins - Gestion des échantillons de médecine de précision
• Université de Californie, San Francisco - Développement de la technologie génomique

Azenta, Inc. (AZTA) - Modèle d'entreprise: Activités clés

Concevoir et fabriquer des équipements de science et de semi-conducteurs de vie

Au cours de l'exercice 2023, Azenta a déclaré des revenus de ventes d'équipements de 340,7 millions de dollars, en mettant l'accent sur les processus de fabrication spécialisés.

Catégorie d'équipement	Volume de production annuel	Lieux de fabrication
Équipement de sciences de la vie	1 200 unités	Woburn, MA et Shanghai, Chine
Équipement de semi-conducteur	850 unités	Billerica, MA

Solutions de gestion et de stockage des échantillons cryogéniques

Azenta exploite 8 installations de biorépositions mondiales avec une capacité de stockage totale de plus de 500 millions d'échantillons biologiques.

• Systèmes de stockage cryogénique déployé dans 42 pays
• Revenus de services de gestion des échantillons annuels: 127,5 millions de dollars
• Plus de 3 500 établissements de recherche et des sociétés pharmaceutiques servies

Recherche et développement des technologies avancées

L'investissement en R&D pour l'exercice 2023 était de 62,4 millions de dollars, ce qui représente 11,6% du total des revenus de l'entreprise.

Zone de focus R&D	Demandes de brevet	Projets de recherche actifs
Technologies cryogéniques	23	12
Traitement des semi-conducteurs	18	9

Processus d'ingénierie et de fabrication de précision

Tolérance de précision de fabrication: ± 0,001 mm à travers les composants de l'équipement critiques.

• ISO 9001: Installations de fabrication certifiée 2015
• Temps moyen du cycle de fabrication: 6-8 semaines
• Taux de rejet du contrôle de la qualité: moins de 0,5%

Services mondiaux de vente et de support client

Couverture des ventes mondiales sur 6 continents avec 247 membres du personnel de vente et de soutien dédié.

Région	Représentants des ventes	Heures de support client annuelles
Amérique du Nord	98	42,500
Europe	67	29,300
Asie-Pacifique	82	36,800

Azenta, Inc. (AZTA) - Modèle d'entreprise: Ressources clés

Ingénierie spécialisée et expertise technique

Azenta, Inc. maintient un main-d'œuvre technique hautement spécialisée avec la composition suivante:

Catégorie des employés	Nombre d'employés
Personnel total de R&D	387
Scientifiques de niveau doctorant	129
Spécialistes de l'ingénierie	258

Installations de fabrication avancées

Azenta exploite plusieurs installations de fabrication avec les spécifications suivantes:

• Emplacements de fabrication totaux: 6
• Régions de fabrication primaires: États-Unis, Chine, Singapour
• Fabrication totale en pieds carrés: 275 000 pieds carrés

Technologies propriétaires

Catégorie de technologie	Nombre de technologies propriétaires
Technologies de stockage cryogénique	17
Technologies d'équipement semi-conducteur	23
Technologies d'automatisation des sciences de la vie	12

Portefeuille de propriété intellectuelle

Les actifs de la propriété intellectuelle d'Azenta comprennent:

• Brevets actifs totaux: 142
• Demandes de brevet en instance: 38
• Familles de brevets: 56

Main-d'œuvre qualifiée

Composition de la main-d'œuvre	Nombre d'employés
Total des employés	1,643
Titulaires de diplômes avancés	412
Spécialistes techniques	987

Azenta, Inc. (AZTA) - Modèle d'entreprise: propositions de valeur

Équipement scientifique de haute précision pour la recherche et les applications cliniques

Azenta propose des équipements scientifiques avec les spécifications suivantes:

Type d'équipement	Niveau de précision	Segment de marché
Systèmes de stockage cryogénique	± 0,1 ° C	Biorépositoire
Exemples de plateformes de gestion	99,9% du suivi de la fiabilité	Laboratoires de recherche
Outils de fabrication de semi-conducteurs	Précision au niveau du nanomètre	Fabrication de haute technologie

Solutions de gestion des échantillons innovants pour les sciences de la vie

Les solutions de gestion des exemples d'Azenta comprennent:

• Systèmes de suivi des échantillons automatisés
• Infrastructure de stockage cryogénique
• Plates-formes de gestion d'échantillons de bout en bout

Technologies de fabrication avancées des semi-conducteurs

Offres de technologie de semi-conducteurs:

Technologie	Métrique de performance	Application de marché
Systèmes de manutention des plaquettes	Compatibilité des plaquettes de 300 mm	Production de semi-conducteurs
Outils d'alignement de précision	Positionnement de submicron	Fabrication avancée des puces

Systèmes de stockage cryogénique fiables et évolutifs

Capacités de stockage cryogénique:

• Capacité de stockage: jusqu'à 10 millions d'échantillons biologiques
• Plage de températures: -190 ° C à + 37 ° C
• Taux de préservation de l'intégrité des échantillons: 99,99%

Solutions technologiques de pointe pour des défis scientifiques complexes

Métriques de la solution technologique:

Catégorie de solution	Capacité technologique	Impact du marché
Automatisation des sciences de la vie	Gestion des échantillons dirigés par AI	Amélioration de l'efficacité de la recherche
Traitement des semi-conducteurs	Manipulation avancée des matériaux	Amélioration de la précision de la fabrication

Azenta, Inc. (AZTA) - Modèle d'entreprise: relations avec les clients

Assistance des ventes directes et consultation technique

Azenta fournit un support direct sur les ventes par le biais d'une équipe dédiée de 87 professionnels des ventes au quatrième trimestre 2023. La société a déclaré 524,7 millions de dollars de revenus totaux pour l'exercice 2023, avec des services de consultation technique spécialisés intégrés dans plusieurs segments d'entreprise.

Métrique du support client	2023 données
Représentants des ventes totales	87
Temps d'interaction du client moyen	2,3 heures par consultation
Temps de réponse technique du support	4,1 heures

Programmes de formation client et d'éducation en cours

Azenta propose des programmes de formation complets à travers les sciences de la vie et les marchés des équipements de semi-conducteurs.

• Sessions de formation annuelles: 42 ateliers
• Modules de formation en ligne: 26 cours numériques
• Platention certifiée Participants: 1 284 en 2023

Service personnalisé pour la recherche et les clients industriels

L'entreprise dessert 1 356 institutions de recherche et clients industriels avec Packages de solutions personnalisées.

Segment client	Nombre de clients	Niveau de personnalisation
Institutions de recherche	782	Haut
Clients industriels	574	Moyen à élevé

Approche de partenariat à long terme

Azenta maintient un taux moyen de rétention de la clientèle de 89,6% entre ses segments d'entreprise, 73 clients ayant des partenariats supérieurs à 10 ans.

Services de soutien technique réactifs et de maintenance

L'infrastructure de support technique comprend 132 ingénieurs de soutien dédiés avec couverture mondiale.

• Centres de soutien mondial: 7 emplacements
• Disponibilité du support technique 24/7
• Time de disponibilité moyen de l'équipement: 97,3%

Métrique de soutien	Performance
Ingénieurs de soutien total	132
Centres de soutien mondiaux	7
Interactions de soutien annuelles	4,672

Azenta, Inc. (AZTA) - Modèle d'entreprise: canaux

Équipe de vente directe

En 2024, Azenta maintient une force de vente directe dédiée d'environ 215 professionnels des ventes sur les marchés mondiaux. L'équipe commerciale se concentre sur les industries des sciences de la vie, des semi-conducteurs et des matériaux avancés.

Région de vente	Nombre de représentants commerciaux
Amérique du Nord	95
Europe	65
Asie-Pacifique	55

Plateformes de commerce électronique en ligne

Azenta exploite plusieurs canaux de vente numériques avec un volume de transactions en ligne annuel de 87,3 millions de dollars en 2023.

• Site Web de l'entreprise (portail de vente directe)
• Marchés spécialisés des équipements scientifiques
• Plates-formes d'approvisionnement numériques

Conférences scientifiques et salons commerciaux

Azenta participe à 42 conférences scientifiques et technologiques internationales chaque année, avec une dépense de marketing estimée à 2,4 millions de dollars.

Réseaux de distributeurs

La société maintient des partenariats avec 87 distributeurs mondiaux d'équipements scientifiques dans 23 pays.

Région	Nombre de distributeurs
Amérique du Nord	28
Europe	32
Asie-Pacifique	27

Canaux de marketing numérique et de communication technique

Azenta exploite plusieurs plateformes de communication numérique avec les mesures d'engagement suivantes:

• LinkedIn adepte: 45 670
• Twitter abonnés: 22 340
• Tescules techniques sur le webinaire (2023): 3 850
• Budget annuel du marketing numérique: 1,7 million de dollars

Azenta, Inc. (AZTA) - Modèle d'entreprise: segments de clientèle

Organisations de recherche pharmaceutique

Azenta sert des organisations de recherche pharmaceutique avec des solutions critiques des sciences de la vie. En 2023, le marché mondial de la recherche pharmaceutique était évalué à 179,4 milliards de dollars.

Type de client	Taille du marché estimé	Taux de pénétration
Top 20 des sociétés pharmaceutiques	98,6 milliards de dollars	54.9%
Organisations de recherche pharmaceutique de taille moyenne	52,3 milliards de dollars	29.1%

Biotechnology Companies

Les sociétés de biotechnologie représentent un segment de clientèle important pour les technologies des sciences de la vie d'Azenta.

• Taille du marché mondial de la biotechnologie en 2023: 627,2 milliards de dollars
• Nombre de sociétés de biotechnologie active dans le monde: 8 442
• Dépenses estimées en R&D: 186,3 milliards de dollars par an

Institutions de recherche universitaires et gouvernementales

Azenta fournit des équipements et des services spécialisés aux institutions de recherche.

Type d'institution	Nombre de clients potentiels	Budget de recherche annuel
Top 100 universités de recherche	100	68,4 milliards de dollars
Laboratoires de recherche gouvernementaux	237	45,7 milliards de dollars

Entreprises de fabrication de semi-conducteurs

La fabrication de semi-conducteurs représente un segment de clientèle croissant pour Azenta.

• Taille du marché mondial des semi-conducteurs en 2023: 573,4 milliards de dollars
• Nombre de fabricants de semi-conducteurs actifs: 332
• Dépenses estimées en équipement: 89,6 milliards de dollars

Laboratoires de soins de santé et cliniques

Les laboratoires cliniques représentent un segment de clientèle essentiel pour les solutions de diagnostic d'Azenta.

Type de laboratoire	Nombre total	Volume de test annuel
Laboratoires de diagnostic clinique	6,773	8,2 milliards de tests par an
Laboratoires hospitaliers	5,534	4,7 milliards de tests par an

Azenta, Inc. (AZTA) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Pour l'exercice 2023, Azenta, Inc. a déclaré des dépenses de R&D de 91,4 millions de dollars, ce qui représente 13,4% des revenus totaux.

Exercice fiscal	Dépenses de R&D	Pourcentage de revenus
2023	91,4 millions de dollars	13.4%
2022	83,2 millions de dollars	12.9%

Frais de fabrication et de production

Les coûts de fabrication totaux pour Azenta en 2023 étaient de 237,6 millions de dollars, avec une ventilation clé comme suit:

• Coûts de main-d'œuvre directs: 68,3 millions de dollars
• Dépenses de matières premières: 112,5 millions de dollars
• Fabrication des frais généraux: 56,8 millions de dollars

Opérations mondiales de vente et de marketing

Les dépenses de vente et de marketing pour Azenta au cours de l'exercice 2023 ont totalisé 129,7 millions de dollars.

Région géographique	Dépenses marketing
Amérique du Nord	62,4 millions de dollars
Europe	37,2 millions de dollars
Asie-Pacifique	30,1 millions de dollars

Maintenance des infrastructures technologiques

La technologie et la maintenance des infrastructures pour 2023 étaient de 45,6 millions de dollars, notamment:

• Mises à niveau des systèmes informatiques: 22,3 millions de dollars
• Investissements en cybersécurité: 12,5 millions de dollars
• Infrastructure cloud: 10,8 millions de dollars

Acquisition et rétention de talents

Les dépenses liées aux ressources humaines et aux talents en 2023 s'élevaient à 96,2 millions de dollars.

Catégorie de dépenses	Montant
Salaires et salaires	76,5 millions de dollars
Avantages sociaux	15,3 millions de dollars
Recrutement et formation	4,4 millions de dollars

Azenta, Inc. (AZTA) - Modèle d'entreprise: Strots de revenus

Ventes d'équipements dans le secteur des sciences de la vie

Pour l'exercice 2023, Azenta a signalé des ventes d'équipements sur les sciences de la vie de 281,4 millions de dollars.

Catégorie de produits	Revenus ($ m)	Pourcentage du total
Systèmes de gestion des échantillons automatisés	156.7	55.7%
Équipement de recherche génomique	124.6	44.3%

Solutions d'équipement semi-conducteur

Les solutions d'équipement semi-conducteur ont généré 202,3 millions de dollars de revenus pour l'exercice 2023.

Segment semi-conducteur	Revenus ($ m)
Équipement d'emballage avancé	112.5
Solutions de test de semi-conducteurs	89.8

Revenus du système de stockage d'échantillon cryogénique

Les systèmes de stockage cryogénique ont contribué 97,6 millions de dollars au chiffre d'affaires total d'Azenta en 2023.

• Solutions de stockage de biorepositif: 62,3 millions de dollars
• Systèmes cryogéniques institutionnels de recherche: 35,3 millions de dollars

Contrats de maintenance et de service en cours

Les contrats de service et de maintenance ont généré 73,8 millions de dollars de revenus récurrents pour l'exercice 2023.

Type de service	Valeur du contrat annuel ($ m)
Entretien de l'équipement	48.5
Contrats de support technique	25.3

Services de licence et de conseil technologique

Les services de licence et de conseil technologiques ont représenté 41,2 millions de dollars en revenus 2023.

• Licence de propriété intellectuelle: 24,7 millions de dollars
• Services de conseil: 16,5 millions de dollars

Revenu annuel total (2023): 696,3 millions de dollars

Azenta, Inc. (AZTA) - Canvas Business Model: Value Propositions

You're looking at the core reasons why pharmaceutical and biotech clients choose Azenta, Inc. for their critical research infrastructure. It's about de-risking their most valuable assets-their biological samples-and speeding up their R&D timelines. The numbers show where the business is focused.

Flawless sample integrity via automated cold-chain management.

This value proposition is anchored in the Sample Management Solutions (SMS) segment, which provides the physical and logistical backbone for sample preservation. The focus here is on reliability at scale, which is essential for multi-year clinical trials and biobanking efforts. The company's ability to maintain viability across ultra-low temperatures is non-negotiable for customers.

The financial contribution from this area for the full fiscal year 2025 was substantial:

Metric	Amount/Value
Full Year Fiscal 2025 SMS Revenue	$325 million
Q3 Fiscal 2025 SMS Revenue	$78 million
Q4 Fiscal 2025 SMS Revenue	$86 million

The Q3 2025 revenue for SMS was down 4% year-over-year, but Q4 saw a rebound with 2% reported growth, showing the lumpy nature of capital equipment sales like Automated Stores.

Accelerating drug discovery with high-throughput multiomics services.

The Multiomics segment is the growth engine, providing the analytical horsepower needed to turn stored samples into actionable data. This includes Next Generation Sequencing (NGS), which has been a consistent performer.

• NGS volume growth was at double-digit rates in Q2 2025.
• NGS pricing showed stabilization for the 4th consecutive quarter as of Q2 2025.
• Q3 Fiscal 2025 Multiomics Revenue was $66 million, up 4% year-over-year.
• Full Year Fiscal 2025 Multiomics Revenue was $269 million, up 6% year-over-year.

This segment's performance is key to the overall organic growth trajectory. For the full year 2025, Azenta, Inc.'s total organic revenue grew 3%.

End-to-end sample lifecycle management for complex therapies.

This value is the sum of both segments, supported by a strong balance sheet to ensure continuity of service, which is critical when managing samples for advanced cell and gene therapies. The company ended fiscal year 2025 with a total balance of cash, cash equivalents, and marketable securities of $546 million.

The overall financial results for the full fiscal year 2025 reflect this integrated approach:

• Full Year Fiscal 2025 Total Revenue: $594 million.
• Full Year Fiscal 2025 Adjusted EBITDA Margin: 11.2%, an improvement of 310 basis points year-over-year.
• Full Year Fiscal 2025 Non-GAAP Diluted EPS: $0.51.

The margin expansion, up 310 basis points for the year, shows the value of operational efficiencies being realized across the entire lifecycle management process.

Reduced time and cost to lead candidates in gene therapy.

Azenta, Inc. directly addresses the timeline and safety concerns in gene therapy development through strategic integrations. For instance, a partnership launched in May 2025 integrates their sequencing capabilities with Form Bio's computational solutions to provide AAV Genome Integrity Characterization using their LAAVA software.

This collaboration is designed to streamline lead candidate selection by providing data-driven insights into AAV capsid contents, aiming to enhance therapeutic safety and manufacturability, which directly translates to reduced development timelines and costs for gene therapy developers.

Enterprise-wide sample intelligence software and informatics.

The informatics layer, which includes software like Freezer Pro and Limfinity, transforms raw sample data into intelligence. This software underpins the reliability of the entire cold-chain service, ensuring data integrity matches sample integrity. While specific revenue for informatics is bundled, the focus on operational improvements across the board supports this value.

The company's commitment to operational excellence is evident in its profitability metrics, which are a direct result of better system utilization and cost execution:

Metric (Continuing Operations)	Q3 Fiscal 2025	Q4 Fiscal 2025
Adjusted EBITDA Margin	12.3%	13%
Non-GAAP Diluted EPS	$0.19	$0.21

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Customer Relationships

You're looking at how Azenta, Inc. (AZTA) structures its interactions across its diverse product and service offerings as of late 2025. The approach is definitely segmented based on the value and complexity of the offering.

For high-value systems, like the Automated Stores and Cryogenic Systems, Azenta, Inc. relies on a dedicated direct sales force. This team manages the complex sales cycle for these capital equipment and the associated storage services. Management noted in their Q4 2025 update that they took decisive steps to reshape the commercial organization, including an expanded field presence, to sharpen go-to-market targeting for fiscal 2025.

The Sample Repository Services (SRS), a key part of the Sample Management Solutions (SMS) segment, necessitates consultative, long-term relationships. These services are foundational to the trust required for long-term sample custody. The revenue performance of this segment, which includes SRS, shows its scale:

Period Ended	Sample Management Solutions Revenue (Millions USD)	Year-over-Year Change
March 31, 2025 (Q2 FY25)	$80	8% increase
June 30, 2025 (Q3 FY25)	$78	4% decrease
September 30, 2025 (Q4 FY25)	$86	2% increase

For consumables and standard services, the relationship leans toward self-service and e-commerce channels. These are the more transactional elements of the business. The growth in these areas, specifically for Consumables and Instruments, was noted as a meaningful contributor to the Q4 2025 results.

Support for the installed base of systems is managed through technical support and service contracts. This ensures uptime and continued use of their hardware and software platforms, such as Freezer Pro and Limfinity. The SMS segment also reports revenue from Product Services, which falls under this relationship type.

Azenta, Inc. maintains definitely collaborative relationships with top pharma, as they provide services to the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. This focus is critical, as the company's overall fiscal year 2025 revenue was $593.8 million, with 39% of that revenue generated outside the United States in fiscal year 2025, showing a growing international footprint with these key customers.

• The company ended the fiscal year 2025 with $546 million in cash, cash equivalents, and marketable securities.
• The debt-to-equity ratio stood at a low 0.03.
• The overall business achieved an Adjusted EBITDA Margin of 11.2% for the full fiscal year 2025.

Finance: review the Q1 2026 sales pipeline against the 3% to 5% organic growth guidance for the full year 2026 by end of January.

Azenta, Inc. (AZTA) - Canvas Business Model: Channels

You're looking at how Azenta, Inc. (AZTA) gets its Sample Management Solutions and Multiomics services into the hands of pharmaceutical and biotech clients as of late 2025. The channels reflect a hybrid approach, mixing direct engagement for high-value services with broader distribution for core products.

The direct sales force targets the two core continuing operations segments. For the third quarter of fiscal year 2025, the Sample Management Solutions segment generated $78 million in revenue, while the Multiomics segment brought in $66 million. The direct team is essential for selling complex, automated cold-chain infrastructure and high-throughput genomic services.

For core products, Azenta, Inc. relies on a trusted network of third-party distributors globally. While the exact number of partners isn't public, this channel helps extend reach for products like consumables and instruments, which contributed to the Sample Management Solutions revenue decline of 4% year-over-year in Q3 fiscal 2025.

The company-owned biorepository and service centers form a critical physical channel, ensuring sample integrity and local access. As of the June 30, 2025, balance sheet date, Azenta, Inc. maintained a cash and liquidity balance of $565 million, supporting this global footprint. The new biorepository in Greater Boston, for instance, is a 40,000 square foot facility.

Here is a look at the known physical channel locations supporting their operations:

Region	City/Site	Type of Facility Mentioned
North America	Burlington, MA	Corporate Headquarters
North America	Indianapolis, IN	Flagship Biorepository
North America	Waltham, MA	Multiomics Location
North America	Research Triangle Park, NC	Laboratory/Facility
North America	Seattle, WA	Laboratory/Facility
Europe	Leipzig, Germany	Laboratory/Facility
Europe	Oxford, United Kingdom	Laboratory/Facility

Investor relations and webcasts serve as the direct channel to the financial community. Management is focused on margin expansion, projecting 300 basis points of Adjusted EBITDA margin expansion for the full fiscal year 2025.

• Azenta Life Sciences Investor Day was scheduled for Wednesday, December 10, 2025, with the webcast presentation starting at 1:00 PM ET.
• The Q4 and Full Year Fiscal 2025 Earnings Conference Call and Webcast was scheduled for Friday, November 21, 2025, at 8:30 AM ET.
• The company's Market Capitalization as of November 21, 2025, was reported at $1.38 billion.

Digital platforms are key for the Multiomics business, which includes the GENEWIZ brand. GENEWIZ from Azenta Life Sciences provides services like Next Generation Sequencing and Gene Synthesis. While the platform facilitates ordering and payment, specific digital ordering volume or user statistics for fiscal 2025 aren't reported.

The digital channel is reinforced through strategic integrations, such as the partnership announced in May 2025 with Form Bio to enhance AAV gene therapy development through an integrated sequencing and data analysis solution. The overall Fiscal 2025 reported revenue was $593.82 million, with a reported loss of -$59.50 million.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Customer Segments

You're looking at the customer base for Azenta, Inc. as of late 2025, which is entirely focused on life sciences, having completed the strategic pivot away from semiconductor automation. The company's total revenue for the fiscal year ending September 30, 2025, reached $593.82M, with an organic growth rate of 3% for that full year. This revenue supports a global customer base, as 39% of total revenue was generated outside the United States in fiscal year 2025.

Azenta, Inc. serves its customers through two primary reporting segments: Sample Management Solutions (SMS) and Multiomics. These segments map directly to the essential needs of drug developers, researchers, and healthcare providers.

The Sample Management Solutions segment is the backbone for customers needing secure, long-term sample integrity. For instance, in the third quarter of fiscal year 2025, this segment generated $78 million in revenue, driven by services like Sample Repository Solutions and Core Products. In the fourth quarter, SMS revenue was $86 million, showing strength in areas like Clinical Biostores and Sample Storage, even with softness in Cryogenic Stores due to customer capital expenditure delays.

The Multiomics segment is the growth engine, focused on genomic services essential for modern therapy development. In the third quarter of fiscal year 2025, Multiomics revenue was $66 million, up 4% year-over-year, primarily fueled by Next Generation Sequencing. This segment directly supports advanced cell and gene therapy developers and large biotech firms needing high-throughput analysis.

Here's a quick look at the segment revenue performance from the third quarter of fiscal 2025, which gives you a clear picture of where the business was at that point:

Segment	Revenue (Q3 FY2025, in millions USD)	Year-over-Year Organic Growth (Q3 FY2025)
Sample Management Solutions	$78	-6%
Multiomics	$66	3%
Total Revenue (Continuing Operations)	$144	-2%

The customer segments are served by specific offerings within these structures. You're looking at a customer base that relies on Azenta, Inc. for mission-critical infrastructure and analysis.

• Top pharmaceutical and biotechnology companies use both segments for drug development pipelines.
• Academic and government research institutions are key users of Multiomics for discovery research.
• Clinical research organizations (CROs) and clinical trial sponsors rely heavily on Sample Management Solutions for trial material integrity.
• Advanced cell and gene therapy developers require Multiomics for sequencing and SMS for ultra-low temperature storage.
• Healthcare institutions and biobanks globally utilize Sample Repository Services and Clinical Biostores.

For the full year 2025, the company reported a strong cash position, ending the year with $283.5 million in cash, cash equivalents, and restricted cash, plus $262.7 million in marketable securities, ensuring they can continue to support these long-term customer relationships.

The Multiomics segment saw particular momentum, with organic revenue growing 10% year-over-year in the fourth quarter of fiscal 2025, driven by Next Generation Sequencing and Gene Synthesis, which are services directly tied to the most innovative drug development efforts.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Cost Structure

You're looking at the core expenses that drive Azenta, Inc.'s operations as of late 2025, focusing on the continuing businesses after the planned divestiture of B Medical Systems. The cost structure reflects a pivot toward high-tech services in Sample Management Solutions (SMS) and Multiomics.

Cost of revenue (COGS) for consumables and instruments is a primary driver. While specific 2025 COGS for consumables and instruments isn't fully itemized separately from the continuing operations' gross margin, we can infer the cost base from recent performance. For the third quarter of fiscal 2025, continuing operations generated revenue of $144 million, with an Adjusted Gross Margin of 48.5%. This implies an Adjusted Cost of Revenue of approximately $74.16 million for that quarter, which covers the direct costs associated with providing sample management products, consumables, and multiomics sequencing services. For context, the Total Cost of Revenue for the full fiscal year 2024 was $393 million on $656 million in total revenue, before the B Medical segment was classified as discontinued. The focus on higher-margin services within SMS and Multiomics is intended to improve this ratio.

Significant R&D investment for automation and multiomics expansion is managed with discipline. In the third quarter of fiscal 2025, Research and Development costs were lower year-over-year, contributing to a 6% decrease in total GAAP Operating Expenses compared to the prior year period. On a Non-GAAP basis for Q3 2025, Adjusted Operating Expense was $62 million, down 4% year-over-year, driven in part by lower R&D costs. This suggests a near-term focus on operational efficiency while maintaining necessary investment in automation for their Sample Management Solutions, such as automated stores and cryogenic systems, and expansion in Multiomics capabilities like Next Generation Sequencing.

Selling, General, and Administrative (SG&A) expenses for global sales are being tightly controlled as part of the transformation program. For Q3 2025, lower Selling, General, and Administrative expenses were a key factor in reducing the Adjusted Operating Expense to $62 million, down from $69 million in Q2 2025. This reduction in SG&A helped drive the Adjusted Operating Margin for Q3 2025 to 5.5% for continuing operations. The global sales force supports the Sample Management Solutions and Multiomics segments across North America, Europe, and Asia.

Operating costs for global biorepository and cold-chain infrastructure are embedded within COGS and operating expenses, reflecting the complexity of maintaining reliable cold-chain custody. The Sample Management Solutions segment revenue, which includes these services, was $78 million in Q3 2025. The company's commitment to this infrastructure is a fixed cost component that underpins the value proposition of sample integrity. Capital expenditures for the full fiscal year 2024 were approximately $38 million, indicating ongoing investment in these physical assets.

Restructuring and portfolio simplification costs (e.g., B Medical sale) have been a notable, though temporary, cost factor. The intention to sell the B Medical Systems segment was announced in fiscal Q1 2025, leading to its classification as a discontinued operation. In Q2 2025, the company noted increased restructuring and transformation charges. However, by Q3 2025, GAAP Operating Expenses reflected lower restructuring charges year-over-year. These charges are adjustments not representative of normal operations, but they impacted the GAAP results, contributing to the total diluted EPS loss of ($0.88) in Q2 2025, which included ($0.49) from discontinued operations.

Here's a quick look at the latest reported operational expense snapshot for continuing operations (Q3 2025):

Metric (Continuing Operations)	Q3 2025 (USD Millions)	Change vs. Q2 2025	Change vs. Q3 2024
Revenue	144	0%	0%
Adjusted Operating Expense	62	Down 10.1%	Down 4%
Adjusted Operating Margin	5.5%	+150 basis points	+340 basis points

The overall financial impact of the 2025 fiscal year, ending September 30, 2025, showed a total Net Loss attributable to common shareholders of -$59.50 million, which was a significant improvement from the -$164 million loss in fiscal year 2024. This reflects the cost discipline applied across the core business as the divestiture process moved forward.

• Total FY 2025 Revenue (All Operations): $593.82 million.
• FY 2024 Total Revenue: $656.32 million.
• Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025: $540 million.
• FY 2025 Organic Revenue Growth Guidance (Reiterated): Range of 3% to 5% relative to fiscal 2024.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Revenue Streams

You're looking at how Azenta, Inc. (AZTA) converts its core life science services into actual dollars as of late 2025. It's all about the two main pillars now that they've streamlined the portfolio. Here's the quick math on where the money came from in fiscal year 2025 (FY25).

The overall picture for FY25 showed reported revenue of $594 million, marking a 4% increase year-over-year from continuing operations. This top-line performance resulted in a Non-GAAP Diluted EPS for the full fiscal year 2025 of $0.51.

The revenue streams are clearly segmented across their two primary business units. You can see the split below:

Revenue Stream Segment	FY25 Reported Revenue (in millions)	Year-over-Year Reported Growth	FY25 Non-GAAP Gross Margin
Sample Management Solutions (SMS)	$325 million	2%	49.3% (Q4'25 SMS Non-GAAP Gross Margin)
Multiomics	$269 million	6%	Not explicitly stated for full year, Q4'25 Non-GAAP Gross Margin was 46.7% (Total)

The Multiomics segment was the primary driver of the overall revenue increase for the full year, showing 6% growth, while SMS grew 2%.

Drilling down into the specifics of how these segments generate revenue, you see a mix of service contracts, product sales, and recurring consumables revenue. For the Multiomics business, the revenue streams are heavily weighted toward high-throughput genomic services:

• Multiomics services revenue: Includes gene sequencing, synthesis, and analysis.
• Next-Generation Sequencing (NGS) services showed impressive momentum, with volume rising 50% year-over-year in the fourth quarter.
• Multiomics delivered record revenue of $73 million in the fourth quarter of 2025.

The Sample Management Solutions revenue stream is more diverse, incorporating both capital equipment sales and ongoing service/consumable revenue. This is where you find the sales of automated storage systems and cryogenic freezers, alongside the critical recurring components.

Recurring revenue from Sample Repository Services (SRS) and consumables is a key component here, providing a more predictable base. Specifically, growth in Clinical Biostores, Consumables and Instruments, and Sample Storage were cited as drivers for the SMS segment in FY25. To be fair, revenue from Cryogenic Systems and Automated Stores was lower in the fourth quarter, but other core products offset that decline.

Here are the key revenue drivers within the SMS segment as reported for the fourth quarter:

• Recurring revenue from Sample Repository Services (SRS).
• Sales of consumables and instruments.
• Revenue from Clinical Biostores.
• Sales of automated storage systems and cryogenic freezers (though Cryogenic Systems revenue was lower in Q4'25).

Finance: draft 13-week cash view by Friday.